CoChat

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Background: Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been hypothesized to significantly potentiate the weight-losing and glycemia control effect, which might offer a new therapeutic option in the treatment of type 2 diabetes. The current meta-analysis aims to synthesize evidence of primary efficacy and safety outcomes through clinically randomized controlled trials to evaluate integrated potency and signaling properties. Method: We conducted comprehensive literature searches in Cochrane Library, Web of Science, Embase and PubMed for relevant literatures investigating the efficacy and/or safety of Tirzepatide published in the English as of May 30, 2023 was retrieved. We synthesized results using standardized mean differences (SMDs) and 95% confidence intervals (95 CIs) for continuous outcomes, and odds ratios (ORs) along with 95 Cis for dichotomous outcomes. All analyses were done using Revman version 5.3, STATA version 15.1 and the statistical package ‘meta’. Results: Participants treated with weekly Tirzepatide achieved HbA1c and body weight target values significantly lower than any other comparator without clinically significant increase in the incidence of hypoglycemic events, serious and all-cause fatal adverse events. However, gastrointestinal adverse events and decreased appetite events were reported more frequently with Tirzepatide treatment than with placebo/controls. Conclusion: The Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, for diabetes therapy has opened a new era on personalized glycemia control and weight loss in a safe manner with broad and promising clinical implications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13098-023-01198-4

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of literature search
Fig. 1 Flowchart of literature searchCC BY · PubMed Central
Fig. 2 Overall summary of risk of bias in the included studies. + : low risk of bias; −: high risk of bias; ?: unclear risk of bias
Fig. 2 Overall summary of risk of bias in the included studies. + : low risk of bias; −: high risk of bias; ?: unclear risk of biasCC BY · PubMed Central
Fig. 3 Summary of quantitative data analysis with Random effects or fixed effects SMD (95% CI) estimate with a p-value for analysis of primary efficacy outcomes. *Statistically significant variables at P value < 0.05. a Fasting serum glucose, b hemoglobin A1c, c body weight, d triglyceride, e HDL cholesterol, f LDL cholesterol
Fig. 3 Summary of quantitative data analysis with Random effects or fixed effects SMD (95% CI) estimate with a p-value for analysis of primary efficacy outcomes. *Statistically significant variables at P value < 0.05. a Fasting serum glucose, b hemoglobin A1c, c body weight, d triglyceride, e HDL cholesterol, f LDL cholesterolCC BY · PubMed Central
Fig. 4 Summary of count data analysis with random effects or fixed effects ORs (95% CI) estimate with a p-value for analysis of primary safety outcomes. *Statistically significant variables at P value < 0.05. a All adverse events, b gastrointestinal events, c decreased appetite, d hypoglycemic events, e discontinuation of therapy, f serious adverse events, g fatal adverse event
Fig. 4 Summary of count data analysis with random effects or fixed effects ORs (95% CI) estimate with a p-value for analysis of primary safety outcomes. *Statistically significant variables at P value < 0.05. a All adverse events, b gastrointestinal events, c decreased appetite, d hypoglycemic events, e discontinuation of therapy, f serious adverse events, g fatal adverse eventCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 64 references

Research works printed but not linked: 1

  1. Targets G. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.

Cited by

See all 64

Metadata

Authors
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q.
Affiliations
  • Chengdu University of Traditional Chinese Medicine (CN)
  • Ya'an Polytechnic College (CN)
  • Sichuan Integrative Medicine Hosipital (CN)
Corresponding author
Chen, Qiu
Venue
Diabetology & Metabolic Syndrome
Published
2023-10-30
Volume
15
Issue
1
Pages
222-222
ISSN
1758-5996 (ISSN-L)
OpenAlex
W4388034622
Cited by
55
References
64
Citations by year
2026: 18 · 2025: 26 · 2024: 10 · 2023: 1
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, type 2 diabetes, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist, incretin-based therapy, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, appetite loss, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1186/s13098-023-01198-4
The paper
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023). Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-023-01198-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.